A Ra Kho

A Ra Kho

Auto-generated profile, based on publicly available information

A Ra Kho

Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Neurotherapeutics
Verified
Journal Article
Open access
HYHyun Wook Yang
Hyun Wook Yang
AKA Ra Kho
A Ra Kho
SLSong Hee Lee
Song Hee Lee
BKBeom Seok Kang
Beom Seok Kang
MPMin Kyu Park
Min Kyu Park
Sang Won SuhSang Won Suh
Sang Won Suh
Epilepsy, a complex neurological disorder, is characterized by recurrent seizures caused by aberrant electrical activity in the brain. Central to this study is the role of lysosomal dysfunction in epilepsy, which can lead to the accumulation of toxic substrates and impaired autophagy in neurons. Our focus is on phosphodiesterase-4 (PDE4), an enzyme that plays a crucial role in regulating intracellular cyclic adenosine monophosphate (cAMP) levels by converting it into adenosine monophosphate (AMP). In pathological states, including epilepsy, increased PDE4 activity contributes to a decrease in cAMP levels, which may exacerbate neuroinflammatory responses. We hypothesized that amlexanox, an anti-inflammatory drug and non-selective PDE4 inhibitor, could offer neuroprotection by addressing lysosomal dysfunction and mitigating neuroinflammation, ultimately preventing neuronal death in epileptic conditions. Our research utilized a pilocarpine-induced epilepsy animal model to investigate amlexanox's potential benefits. Administered intraperitoneally at a dose of 100 ​mg/kg daily following the onset of a seizure, we monitored its effects on lysosomal function, inflammation, neuronal death, and cognitive performance in the brain. Tissue samples from various brain regions were collected at predetermined intervals for a comprehensive analysis. The study's results were significant. Amlexanox effectively improved lysosomal function, which we attribute to the modulation of zinc's influx into the lysosomes, subsequently enhancing autophagic processes and decreasing the release of inflammatory factors. Notably, this led to the attenuation of neuronal death in the hippocampal region. Additionally, cognitive function, assessed through the modified neurological severity score (mNSS) and the Barnes maze test, showed substantial improvements after treatment with amlexanox. These promising outcomes indicate that amlexanox has potential as a therapeutic agent in the treatment of epilepsy and related brain disorders. Its ability to combat lysosomal dysfunction and neuroinflammation positions it as a potential neuroprotective intervention. While these findings are encouraging, further research and clinical trials are essential to fully explore and validate the therapeutic efficacy of amlexanox in epilepsy management.

Verified
Journal Article
Open access
PDF file
SLSi Hyun Lee
Si Hyun Lee
AKA Ra Kho
A Ra Kho
SLSong Hee Lee
Song Hee Lee
DHDae Ki Hong
Dae Ki Hong
BKBeom Seok Kang
Beom Seok Kang
Sang Won SuhSang Won Suh
Sang Won Suh
Traumatic brain injury (TBI) broadly degrades the normal function of the brain after a bump, blow, or jolt to the head. TBI leads to the aggravation of pre-existing brain dysfunction and promotes neurotoxic cascades that involve processes such as oxidative stress, loss of dendritic arborization, and zinc accumulation. Acid sphingomyelinase (ASMase) is an enzyme that hydrolyzes sphingomyelin to ceramide in cells. Under normal conditions, ceramide plays an important role in various physiological functions, such as differentiation and apoptosis. However, under pathological conditions, excessive ceramide production is toxic and activates the neuronal-death pathway. Therefore, we hypothesized that the inhibition of ASMase activity by imipramine would reduce ceramide formation and thus prevent TBI-induced neuronal death. To test our hypothesis, an ASMase inhibitor, imipramine (10 mg/kg, i.p.), was administrated to rats immediately after TBI. Based on the results of this study, we confirmed that imipramine significantly reduced ceramide formation, dendritic loss, oxidative stress, and neuronal death in the TBI-imipramine group compared with the TBI-vehicle group. Additionally, we validated that imipramine prevented TBI-induced cognitive dysfunction and the modified neurological severity score. Consequently, we suggest that ASMase inhibition may be a promising therapeutic strategy to reduce hippocampal neuronal death after TBI.

5 November 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
DHDae Ki Hong
Dae Ki Hong
JEJae-Won Eom
Jae-Won Eom
AKA Ra Kho
A Ra Kho
SLSong Hee Lee
Song Hee Lee
BKBeom Seok Kang
Beom Seok Kang
Sang Won SuhSang Won Suh
Sang Won Suh
AMP-activated protein kinase (AMPK) is necessary for maintaining a positive energy balance and essential cellular processes such as glycolysis, gene transcription, glucose uptake, and several other biological functions. However, brain injury-induced energy and metabolic stressors, such as cerebral ischemia, increase AMPK phosphorylation. Phosphorylated AMPK contributes to excitotoxicity, oxidative, and metabolic problems. Furthermore, brain disease-induced release of zinc from synaptic vesicles contributes to neuronal damage via mechanisms including ROS production, apoptotic cell death, and DNA damage. For this reason, we hypothesized that regulating zinc accumulation and AMPK phosphorylation is critical for protection against global cerebral ischemia (GCI). Through virtual screening based on the structure of AMPK subunit alpha 2, we identified a novel compound, 2G11. In this study, we verified that 2G11 administration has neuroprotective effects via the blocking of zinc translocation and AMPK phosphorylation after GCI. As a result, we demonstrated that 2G11 protected hippocampal neurons against GCI and OGD/R-derived cellular damage. In conclusion, we propose that AMPK inhibition and zinc chelation by 2G11 may be a promising tool for preventing GCI-induced hippocampal neuronal death.

13 November 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
SLSong Hee Lee
Song Hee Lee
Bo Young ChoiBo Young Choi
Bo Young Choi
AKA Ra Kho
A Ra Kho
DHDae Ki Hong
Dae Ki Hong
BKBeom Seok Kang
Beom Seok Kang
Sang Won SuhSang Won Suh
Sang Won Suh
During seizure activity, glucose and Adenosine triphosphate (ATP) levels are significantly decreased in the brain, which is a contributing factor to seizure-induced neuronal death. Dichloroacetic acid (DCA) has been shown to prevent cell death. DCA is also known to be involved in adenosine triphosphate (ATP) production by activating pyruvate dehydrogenase (PDH), a gatekeeper of glucose oxidation, as a pyruvate dehydrogenase kinase (PDK) inhibitor. To confirm these findings, in this study, rats were given a per oral (P.O.) injection of DCA (100 mg/kg) with pyruvate (50 mg/kg) once per day for 1 week starting 2 h after the onset of seizures induced by pilocarpine administration. Neuronal death and oxidative stress were assessed 1 week after seizure to determine if the combined treatment of pyruvate and DCA increased neuronal survival and reduced oxidative damage in the hippocampus. We found that the combined treatment of pyruvate and DCA showed protective effects against seizure-associated hippocampal neuronal cell death compared to the vehicle-treated group. Treatment with combined pyruvate and DCA after seizure may have a therapeutic effect by increasing the proportion of pyruvate converted to ATP. Thus, the current research demonstrates that the combined treatment of pyruvate and DCA may have therapeutic potential in seizure-induced neuronal death.

8 February 2025 in Phytomedicine
Verified
Journal Article
Open access
MPMin Kyu Park
Min Kyu Park
Bo Young ChoiBo Young Choi
Bo Young Choi
AKA Ra Kho
A Ra Kho
SLSong Hee Lee
Song Hee Lee
DHDae Ki Hong
Dae Ki Hong
Sang Won SuhSang Won Suh
Sang Won Suh
Traumatic brain injury (TBI) is a major health concern, often resulting in significant brain damage and functional impairments. A key contributing factor to TBI-induced neuronal injury is the overactivation of AMPA glutamate receptors, leading to an increased influx of calcium and zinc ions. This study investigates the neuroprotective potential of l-theanine, known for its antioxidant potential and ability to enhance glutathione synthesis, against hippocampal damage in a TBI rat model. Rats subjected to TBIs were treated with two dosages of l-theanine (100 and 200 mg/kg) and an AMPA receptor inhibitor, NBQX (30 mg/kg). The neuronal damage assessment, conducted 24 h post-injury, involved a histological analysis, focusing on the factors of neuronal death, oxidative damage, and glial cell activation. The statistical analysis included the performance of an ANOVA followed by a Bonferroni post hoc test, with the data presented as mean ± SEM values and the significance determined at p < 0.05. Treatment with l-theanine was observed to significantly mitigate the zinc accumulation, neuronal death, and cognitive impairments associated with TBI. These benefits are likely attributed to the inhibition of AMPA receptor activity and reduction in neuroinflammation, possibly enhanced as a result of increased glutathione production. This study suggests that l-theanine can perform a neuroprotective role in TBI, modulating AMPA receptor activation and diminishing neuroinflammation. Its antioxidant and anti-inflammatory properties further enhance the material's potential use as a therapeutic agent for reducing hippocampal damage caused as a result of a TBI.

24 March 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
CLChang-Jun Lee
Chang-Jun Lee
SLSong-Hee Lee
Song-Hee Lee
BKBeom-Seok Kang
Beom-Seok Kang
MPMin-Kyu Park
Min-Kyu Park
HYHyun-Wook Yang
Hyun-Wook Yang
Sang Won SuhSang Won Suh
Sang Won Suh
Epilepsy, marked by abnormal and excessive brain neuronal activity, is linked to the activation of L-type voltage-gated calcium channels (LTCCs) in neuronal membranes. LTCCs facilitate the entry of calcium (Ca2+) and other metal ions, such as zinc (Zn2+) and magnesium (Mg2+), into the cytosol. This Ca2+ influx at the presynaptic terminal triggers the release of Zn2+ and glutamate to the postsynaptic terminal. Zn2+ is then transported to the postsynaptic neuron via LTCCs. The resulting Zn2+ accumulation in neurons significantly increases the expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits, contributing to reactive oxygen species (ROS) generation and neuronal death. Amlodipine (AML), typically used for hypertension and coronary artery disease, works by inhibiting LTCCs. We explored whether AML could mitigate Zn2+ translocation and accumulation in neurons, potentially offering protection against seizure-induced hippocampal neuronal death. We tested this by establishing a rat epilepsy model with pilocarpine and administering AML (10 mg/kg, orally, daily for 7 days) post-epilepsy onset. We assessed cognitive function through behavioral tests and conducted histological analyses for Zn2+ accumulation, oxidative stress, and neuronal death. Our findings show that AML’s LTCC inhibition decreased excessive Zn2+ accumulation, reactive oxygen species (ROS) production, and hippocampal neuronal death following seizures. These results suggest amlodipine’s potential as a therapeutic agent in seizure management and mitigating seizures’ detrimental effects.